SOHO 2022 | Insights into the BRUIN CLL-322 trial
William Wierda
• 28 Sep 2022
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the Phase III BRUIN CLL-322 trial (NCT04965493), which is evaluating the safety and efficacy of pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab alone in patients with chronic lymphocytic leukemia (CLL) who have been previously treated with a BTK inhibitor. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
